David A. Cory, RPh, MBA
President and Chief Executive Officer, Director, Business Founder
David Cory is an industry veteran with over 25-years of experience in large pharmaceuticals, emerging stage biotechnology, and specialty pharmaceutical organizations with an established track record of operational performance, including 5 successful Orphan Designation drug programs.
Cory is President and CEO, Director, and business founder of Eiger BioPharmaceuticals, leading the company since founding and responsible for negotiating the company’s multiple technology and product licenses from Stanford University, Merck, Nippon Kayaku, and Janssen. Previously, Cory was CEO of DiObex, a metabolic disease company. Cory was President and Chief Operating Officer of Prestwick Pharmaceuticals, an Orphan CNS specialty pharmaceutical company, which was acquired by Biovail for $160 million. Cory was Co-Founder and Acting Chief Commercial Officer at CoTherix, an Orphan Pulmonary Arterial Hypertension company, which was acquired by Actelion for $425 million. Cory began his start up career at InterMune, focused on developing Orphan products for Idiopathic Pulmonary Fibrosis, where he was a Senior Vice President, and a key executive in the company IPO, building and managing the company’s commercial organization, in-licensing 4 products and raising over $400 million in the capital markets. InterMune was acquired by Roche for $8 billion. Cory began his large pharma career in operating positions of increasing responsibility at The Upjohn Company, Glaxo, Glaxo Wellcome, and Glaxo Smith Kline where he led teams in CNS, Critical Care, Oncology, Infectious Disease, and Respiratory therapeutic areas, and directed 10 pharmaceutical product launches including Flolan (epoprostenol), the first Orphan Designation therapy approved for Pulmonary Arterial Hypertension.
David Cory earned a BS from the University of Cincinnati, College of Pharmacy and an MBA from the University of Maryland, University College.
James A. Welch
Chief Financial Officer
James Welch brings over 20 years of healthcare financial and business experience in diagnostics, emerging biotechnology and specialty pharmaceutical companies, including a decade as a public company CFO, raising over $500 million in 2 IPOs, multiple public secondary offerings and private financings. Prior to Eiger, Mr. Welch served as Chief Financial Officer and Corporate Secretary of Virobay Incorporated. Previously, Mr. Welch served as Chief Financial Officer of Acelrx Pharmaceuticals, Chief Financial Officer and Corporate Secretary at Cerimon Pharmaceuticals, Chief Financial Officer and Corporate Secretary at Rigel Pharmaceuticals, and earlier in his career was the Chief Financial Officer of Biocircuits diagnostics.
James Welch received a B.A. in Business Administration from Whitworth College and an M.B.A. from Washington State University.
James P. Shaffer, MBA
Chief Business Officer
James Shaffer brings extensive commercial leadership and business experience with over 20 years of experience with large pharmaceuticals, emerging biotechnology and specialty pharmaceutical companies in Infectious Disease, Neurology, Oncology, GI and Pulmonary Care.
Prior to joining Eiger, Mr. Shaffer served as Vice President and Chief Commercial Officer for Halozyme Therapeutics from 2011 to 2014 where he was responsible for Sales, Marketing and Business Development overseeing the re-launch of Hylenex® and product development in Diabetes and Oncology. From 2007-2011, Mr. Shaffer was Executive Vice President and Chief Commercial Officer responsible for Sales, Marketing, Business Development and Manufacturing with Clinical Data, Inc., who developed Viibryd®, a novel antidepressant, which was acquired by Forest Laboratories for $1.2 billion. Mr. Shaffer was Vice President of Commercial Operations for New River Pharmaceuticals which developed Vyvanse® for the treatment of ADHD and was acquired by Shire for $2.6 billion in 2007. From 2004-2007, he was Senior Director of Commercial Operations for Prestwick Pharmaceuticals overseeing the collaboration with Cambridge Labs for Xenazine®, an Orphan CNS specialty product, and responsible for the development of the companies commercial capabilities in the US and Canada. From 2001-2004, Mr. Shaffer was the National Sales Director for InterMune. Mr. Shaffer spent the first 10 years of his career in numerous sales and marketing positions of increasing responsibility with Merck and GlaxoSmithKline.
James Shaffer is a graduate of the Ohio State University where he earned a B.S. Degree in Economics and an M.B.A..
Joanne Quan, MD
Chief Medical Officer
Joanne Quan has over 20 years of medical and pharmaceutical industry experience in clinical development and regulatory affairs.
Dr. Quan was most recently Vice President, New Product Clinical Development at InterMune. Previously, she was Vice President, Clinical Development at Arena Pharmaceuticals and led the collaboration with Eisai for lorcaserin (Belviq®) as well as pipeline planning for Arena, including initiation of a Phase 2 program in Pulmonary Arterial Hypertension (PAH). Prior to this, Dr. Quan held scientific, clinical and regulatory positions of increasing responsibility at Bayhill Therapeutics, Alza (Johnson and Johnson), Genentech, and PathoGenesis. She has led multiple successful collaborations and project teams, several IND/CTA submissions and designed, conducted and analyzed numerous Phase 1-4 clinical trials in multiple therapeutic areas, many in Orphan diseases.
Joanne Quan received a B.A. in Molecular Biology at the University of California, Berkeley and an M.D. at Stanford University School of Medicine. She completed a residency in Internal Medicine at Massachusetts General Hospital and a fellowship in Pulmonary and Critical Care Medicine at the University of Washington, Seattle.
Eduardo Martins, MD, DPhil
Senior Vice President, Liver and Infectious Diseases
Dr. Martins has over 15 years U.S. and global biotechnology and pharmaceutical industry experience in translational clinical research, clinical development and medical affairs in various therapeutic areas, including HCV, HBV, influenza, allergy, immunology, and vaccines.
Dr. Martins was most recently the Senior Director, Medical Affairs for Hepatitis at Gilead Sciences where he oversaw a large global clinical trial in HBV, supervised multiple Phase 4 studies in viral hepatitis, and collaborations with drug discovery, translational research, and clinical development in viral hepatitis. Previously, he was the Senior International Medical Leader for Pegasys® (pegylated interferon alfa-2a) at Genentech. Prior to joining Genentech, Dr. Martins worked in positions of increasing responsibility at Dynavax Technologies, InterMune, and SciClone Pharmaceuticals, primarily focused on vaccines and therapeutics for viral hepatitis.
Eduardo Martins received an M.D. from the Medical School, Federal University of Rio de Janeiro, Brazil and a D.Phil. in Immunology of Liver Diseases from the University of Oxford, United Kingdom. He completed specialty training in Gastroenterology and Hepatology at John Radcliffe Hospital, Oxford, United Kingdom.
Debra Odink, PhD
Senior Vice President, Technical Operations
Dr. Odink has nearly 25 years of pharmaceutical and development experience. Most recently, Dr. Odink was the Chief Technical Officer and Senior Vice President at Anthera Pharmaceuticals responsible for manufacturing, clinical and non-clinical operations for the company’s biologic programs (blisibimod and Sollupra™). Previous roles include Vice President of Pharmaceutical Chemistry and Product Development at Peninsula Pharmaceuticals, acquired by Johnson and Johnson in 2005, and senior positions at Roche and Elan Pharmaceuticals. Dr. Odink has directed the pharmaceutical development and manufacturing activities for many global development programs, participated in licensing and supply agreement negotiations, due diligence efforts and led several meetings with the FDA on CMC related topics. Additionally, Dr. Odink was co-founder of a pharmaceutical services company which has become a well-known service provider to many bay area companies. Dr. Odink has provided consulting services to a variety of biopharmaceutical start-up companies leveraging her development and strategic planning experience. Dr. Odink obtained her Bachelor of Science in Chemistry at California State University, Stanislaus and her Ph.D. in Inorganic Chemistry at the University of California, Davis.
Shelly Xiong, PhD, RAC
Vice President, Regulatory Affairs
Shelly Xiong has over 20 years of pharmaceutical industry experience in virology, clinical development, and regulatory affairs spanning Asia, Europe, and North America.
Dr. Xiong most recently served as Director of Regulatory Affairs at InterMune where she was responsible for establishing and managing the product labeling function for European and Canadian commercialization and US labeling preparation for Esbriet® NDA for Idiopathic Pulmonary Fibrosis. Previously, she served as Director of China Operations at Covance in Shanghai, responsible for business strategy, client and government interactions. Dr. Xiong was at Gilead for 15 years, where she held positions in Clinical Virology and Regulatory Affairs, leading the clinical virology development program for Hepsera® for HBV from Phase 2 through product approval. She was involved in multiple IND and NDA filings as well as commercial product labeling for antiviral programs in the US with FDA and in China with CFDA while at Gilead.
Dr. Xiong has extensive experience in drug discovery and development in viral diseases including HBV, HCV, HIV, and CMV. She is an author on over 30 publications in scientific journals and publications.
Shelly Xiong received her Ph.D. in Biochemistry from University of Wisconsin-Madison and B.S. in Chemistry from Beijing University.